Bioventus Inc. (BVS) vs Seaport Therapeutics, Inc. Common Stock (SPTX)
A side-by-side comparison of Bioventus Inc. and Seaport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BVS
Bioventus Inc.
$13.10HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SPTX
Seaport Therapeutics, Inc. Common Stock
$17.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BVS vs SPTX
growth of $100 · dividends reinvested · last 1yBVS +33.7% (+33.7%/yr)SPTX -6.8% (-6.8%/yr)BVS compounded faster over this window
BVS SPTX
BVS vs SPTX: by the numbers
- •SPTX is the larger company ($930M vs $887M market cap).
- •BVS is profitable (9.36% net margin) while SPTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BVS | SPTX |
|---|---|---|
| P/E ratio | 17.01 | N/A |
| Forward P/E | 16.82 | N/A |
| P/S ratio | 1.53 | N/A |
| P/B ratio | 3.89 | 2.20 |
| EV / EBITDA | 10.48 | N/A |
| FCF yield | 10.62% | N/A |
Profitability
| Metric | BVS | SPTX |
|---|---|---|
| Gross margin | 68.00% | 0.00% |
| Operating margin | 10.63% | 0.00% |
| Net margin | 9.36% | 0.00% |
| ROE | 23.86% | N/A |
| ROIC | 11.37% | -36.95% |
Growth (annualized)
| Metric | BVS | SPTX |
|---|---|---|
| Revenue CAGR (5Y) | 11.82% | N/A |
| EPS CAGR (5Y) | -5.03% | N/A |
| FCF CAGR (5Y) | 43.36% | N/A |
| Total return CAGR (5Y) | -0.81% | N/A |
Frequently asked
- Is BVS or SPTX more profitable?
- BVS runs the higher net margin — BVS at 9.36% versus SPTX at 0.00%.
Go deeper
Dig into the metrics
Bioventus P/E ratioBioventus ROESeaport Therapeutics, Inc. Common Stock ROEBioventus operating marginSeaport Therapeutics, Inc. Common Stock operating marginBioventus revenue growthSeaport Therapeutics, Inc. Common Stock revenue growthBioventus free cash flowSeaport Therapeutics, Inc. Common Stock free cash flow
Bioventus & Seaport Therapeutics, Inc. Common Stock appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.